Compass Therapeutics (CMPX)

Executive Summary

Compass Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody therapies for cancer. Leveraging its proprietary platform, the company aims to optimize the tumor microenvironment and bridge innate and adaptive immune responses. Its lead product candidate, CTX-009, is a bispecific antibody targeting DLL4 and VEGF, being evaluated in multiple indications including biliary tract cancer (BTC), colorectal cancer (CRC), and glioblastoma. Compass also has early-stage programs: CTX-8371, a PD-1/PD-L1 bispecific, and CTX-10726, a novel immune checkpoint inhibitor, both in Phase 1 trials. The company is publicly traded (CMPX) with a market cap of approximately $330 million. Key near-term milestones include a Phase 2/3 readout for CTX-009 in biliary tract cancer (completion expected in late 2025) and a Phase 2 data presentation in metastatic colorectal cancer. The Phase 1 programs for CTX-8371 and CTX-10726 are also progressing, with initial data anticipated in 2026. Compass has demonstrated a manageable safety profile for CTX-009, and positive efficacy data could significantly enhance its valuation. However, as a small-cap biotech, the stock remains sensitive to trial outcomes. Overall, Compass Therapeutics presents a risk-reward opportunity centered on its innovative bispecific platform and upcoming catalysts.

Upcoming Catalysts (preview)

• Q2 2026CTX-009 + Paclitaxel Phase 2/3 top-line data in biliary tract cancer60% success
• Q1 2026CTX-009 Phase 2 data presentation in metastatic colorectal cancer55% success
• H2 2026CTX-8371 Phase 1 dose escalation data50% success